Pfizer Inc.
Methods for purifying FXa variant proteins
Last updated:
Abstract:
Compositions are provided comprising recombinant variants of the human clotting Factor Xa. Such compositions include a wide variety of isoforms and post-translational modifications of FXa and are useful for treating subjects in need of hemostasis.
Status:
Grant
Type:
Utility
Filling date:
4 Aug 2017
Issue date:
26 May 2020